Work

Supplementary Figure 2 from A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)

Year: 2023

Type: supplementary-materials

Abstract: Quantification of quality of life score. (A-F) EORTC-Q30 parsed by predefined subgroups (bottom panel) FACT-Leu trial outcome index (TOI)

DOI: 10.1158/1078-0432.22462736.v1

Authors: Eric Padron, Amy Dezern, Marcio Andrade-Campos, Kris Vaddi, Peggy Scherle, Qing Zhang, Yan Ma, Maria E. Balasis, Sara Tinsley, Hanadi Ramadan, Cassandra Zimmerman, David P. Steensma, Gail J. Roboz, Jeffrey E. Lancet, Alan F. List, Mikkael A. Sekeres, Rami S. Komrokji

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361968124

Cites:

Cited by:

Related to: 10